$7.76-4.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Company outlook: revenue of $224M to $227M for Fiscal year 2026 — down 1.3% on a year earlier ($228.4M)
Just reported
From Puma Biotechnology, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$55.1M
+1.1% y/y
-2.6% q/q
Guided
$57.5M
midpoint
Actual
$0.11
-35% y/y
-31% q/q
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $55.1M | $54.5M | +1.07% |
| Profit | $6M | $8.8M | -32.65% |
| Profit per share | $0.11 | $0.17 | -35.29% |
| Free Cash Flow | $14.6M | $9.7M | +50.87% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Puma Biotechnology, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Puma Biotechnology, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Actual
$5.3M
-45% y/y
-30% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.